Phenotypes associated with this allele

• Allele Symbol: Ifnar2^tm1Pjh
• Allele Name: targeted mutation 1, Paul J Hertzog
• Allele ID: MGI:2680693
• Summary: 3 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
hm1	Ifnar2^tm1Pjh/Ifnar2^tm1Pjh	B6.Cg-Ifnar2^tm1Pjh	MGI:3776810
hm2	Ifnar2^tm1Pjh/Ifnar2^tm1Pjh	involves: C57BL/6	MGI:3776848
cx3	Ifnar2^tm1Pjh/Ifnar2^tm1Pjh Il6st^tm1Ern/Il6st^tm1Ern	involves: 129S1/Sv	MGI:4939801

Genotype
MGI:3776810

hm1

• Allelic Composition: Ifnar2^tm1Pjh/Ifnar2^tm1Pjh
• Genetic Background: B6.Cg-Ifnar2^tm1Pjh

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

immune system

decreased NK cell number ( J:125812 )

• the number of NK cells in the spleen is reduced by about a third compared to wild-type mice

impaired natural killer cell mediated cytotoxicity ( J:125812 )

• the ability of splenocytes to induce lysis of the NK target cells is reduced by half or more

• however, when NK cells are purified from the spleen and added into co-culture with NK target cells at the same number as wild-type cells, the lysis rate of the target cells is similar

neoplasm

increased incidence of induced tumors ( J:125812 )

• 2- to 3- fold more mice develop fibrosarcomas 4 months after treatment with 3-methycholanthrene compared to wild-type controls

increased incidence of tumors by chemical induction ( J:125812 )

• there is a 100% incidence of lymphoma after tumor cell transfer compared to only 9% incidence in wild-type mice

• graded doses with a tumor cell line reveal that NK-mediated tumor rejection occurs with slower kinetics

• NK-mediated tumor rejection responds poorly to IL-2 supplementation in vivo

homeostasis/metabolism

increased incidence of tumors by chemical induction ( J:125812 )

• there is a 100% incidence of lymphoma after tumor cell transfer compared to only 9% incidence in wild-type mice

• graded doses with a tumor cell line reveal that NK-mediated tumor rejection occurs with slower kinetics

• NK-mediated tumor rejection responds poorly to IL-2 supplementation in vivo

hematopoietic system

decreased NK cell number ( J:125812 )

• the number of NK cells in the spleen is reduced by about a third compared to wild-type mice

impaired natural killer cell mediated cytotoxicity ( J:125812 )

• the ability of splenocytes to induce lysis of the NK target cells is reduced by half or more

• however, when NK cells are purified from the spleen and added into co-culture with NK target cells at the same number as wild-type cells, the lysis rate of the target cells is similar

Genotype
MGI:3776848

hm2

• Allelic Composition: Ifnar2^tm1Pjh/Ifnar2^tm1Pjh
• Genetic Background: involves: C57BL/6

immune system

decreased IgG level ( J:132662 )

• serum titers of antigen specific IgG in response to a DNA vaccine are 10-fold less

decreased IgG1 level ( J:132662 )

• serum titers of antigen specific IgG1 in response to a DNA vaccine are 10-fold less

decreased IgG2a level ( J:132662 )

• serum titers of antigen specific IgG2a in response to a DNA vaccine are significantly less

abnormal CD4-positive, alpha-beta T cell physiology ( J:132662 )

• CD4 T cells from mice immunized with a DNA vaccine produce significantly less IFN-gamma upon stimulation with antigen in culture

abnormal cytotoxic T cell physiology ( J:132662 )

• CD8 T cells from mice immunized with a DNA vaccine produce significantly less IFN-gamma upon stimulation with antigen in culture compared to vaccinated controls

• there is a 4-fold reduction in the number of antigen specific CD8 T cells two weeks after immunization with a DNA vaccine compared to vaccinated controls

decreased interferon-gamma secretion ( J:132662 )

• splenocytes from mice immunized with a DNA vaccine produce significantly less IFN-gamma upon stimulation with antigen in culture compared to vaccinated controls

• a similar reduction in IFN-gamma secretion from vaccinated mice is observed for both purified CD4 and CD8 T cells upon stimulation with antigen in culture

hematopoietic system

decreased IgG level ( J:132662 )

• serum titers of antigen specific IgG in response to a DNA vaccine are 10-fold less

decreased IgG1 level ( J:132662 )

• serum titers of antigen specific IgG1 in response to a DNA vaccine are 10-fold less

decreased IgG2a level ( J:132662 )

• serum titers of antigen specific IgG2a in response to a DNA vaccine are significantly less

abnormal CD4-positive, alpha-beta T cell physiology ( J:132662 )

• CD4 T cells from mice immunized with a DNA vaccine produce significantly less IFN-gamma upon stimulation with antigen in culture

abnormal cytotoxic T cell physiology ( J:132662 )

• CD8 T cells from mice immunized with a DNA vaccine produce significantly less IFN-gamma upon stimulation with antigen in culture compared to vaccinated controls

• there is a 4-fold reduction in the number of antigen specific CD8 T cells two weeks after immunization with a DNA vaccine compared to vaccinated controls

Genotype
MGI:4939801

cx3

• Allelic Composition: Ifnar2^tm1Pjh/Ifnar2^tm1Pjh; Il6st^tm1Ern/Il6st^tm1Ern
• Genetic Background: involves: 129S1/Sv

mortality/aging

increased susceptibility to xenobiotic induced morbidity/mortality ( J:168781 )

• mice fail to survive beyond 72 hours after treatment with an LPS dose that is sub-lethal to wild-type mice

immune system

increased circulating interleukin-6 level ( J:168781 )

• in LPS-treated mice

increased susceptibility to endotoxin shock ( J:168781 )

• mice fail to survive beyond 72 hours after treatment with an LPS dose that is sub-lethal to wild-type mice

• LPS-treated mice exhibit an increase in IL6 serum levels compared with similarly treated wild-type mice

homeostasis/metabolism

increased circulating interleukin-6 level ( J:168781 )

• in LPS-treated mice

increased susceptibility to xenobiotic induced morbidity/mortality ( J:168781 )

• mice fail to survive beyond 72 hours after treatment with an LPS dose that is sub-lethal to wild-type mice